Since time immemorial, technology has been improving the lives of mankind as it gives way for progression for the sake of convenience. It then spread its scope and worked its wonders in various industries such as mining and biotech to develop innovations that can grant companies new ways to help people in their respective functions.
The biotech industry, particularly, has benefited a lot from technological advancements through the course of time because it led to many inventions such as various medical equipment and medicines, which significantly helped people in treating diseases ranging from simple ones like colds to life-threatening illnesses like cancer. With this fact, technology has helped doctors and medical institutions save lives and give hope to those who felt helpless because of their diseases.
The year 2017 saw a lot of innovations from biotech companies aimed towards prolonging and improving lives. Some of these inventions include a test for fertility concerns and a device in checking a person’s blood glucose.
Back in January 2017, a New York City-based biotech startup called Celmatix announced the launch of its in-depth screen that relies on genetics to acquire information in order to understand and address problems revolving around fertility. The test is called Fertilome.
With the use of DNA obtained from blood, Fertilome can provide women some understanding to assist them in maintaining their reproductive health on the positive side of the spectrum and extending their capability of being fertile.
It can also show those women who are undergoing reproductive problems or those who are still planning to have more kids within the age bracket of 30 to 40 years old if they now have indications connected to reproductive diseases like endometriosis and polycystic ovarian syndrome.
Piraye Yurttas Beim, the CEO of Celmatix, wants Fertilome to become a reliable and recommended tool for doctors to use in spotting any fertility issues in women, per Business Insider. And once that outcome happens, it will attract a lot of profit towards the company, making it a good choice for investors. The test is priced at $950. However, insurances do not cover the test yet.
Abbott Laboratories’ Freestyle Libre Flash Glucose Monitoring System
A veteran of the health industry, Abbott Laboratories has developed a new device that gave more convenience and lessened the pain in checking blood glucose levels, EndocrineWeb reported. This device is called the FreeStyle Libre Flash Glucose Monitoring System.
The U.S. Food and Drug Administration (FDA) recently gave its approval to the said monitoring system. Abbott has stated that possibly by early 2018, people can purchase the device in American pharmacies.
No information has been released concerning the FreeStyle Libre Flash. But according to Abbott Diabetes Care biosensor technology director Chris Thomas, the price is estimated to be the same as the FreeStyle Libre in Europe. The said system cost at around $362, and that comes with 14 days of round-disc sensors and the reader itself.
People use the FreeStyle Libre Flash by putting the sensor on the back of the upper arm, allowing for a real-time measurement of the glucose levels. The sensor can get readings even with obstructions like clothing. The reader that comes with the sensors in the package will indicate the numbers in actuality. However, what is different between the British and the American versions of the system is that the American version’s sensor can only be worn for 10 days, which is shorter than the British version’s 14 days. The American version is also approved for the use of adults aging at 18 years and higher who are afflicted with diabetes.
The FreeStyle Libre Flash will help not only patients with diabetes but also Abbott Laboratories. Forbes reported in 2017 that the company already received a 25 percent increase in its foreign diabetes care sales in the second quarter of the same year, and it also said that the predecessor, the FreeStyle Libre, is responsible for the majority of that percentage.
With the launch of the FreeStyle Libre Flash in the U.S., it can help Abbott Laboratories maintain the upward trajectory that the company’s diabetes care sales are heading. And because of the monitoring system possibly connected to diabetes patients’ improved results about their health, there is the anticipation that the demand for the device in the U.S. will be high.
Cannabidiol in food: While CBD business is booming in America, Germany gets left behind
West Coast Ventures Group Corp. (OTC: WCVC) is America’s first CBD restaurant stock. In their first year of operations alone...
Sweet taste of India: When western chocolate meets the orient
With India’s society on the rise, many people are now looking for a premium sweet treat: chocolates. Today, premium chocolate...
New quality-of-life facilities in demand throughout the U.S.
Municipal leaders and local governments are creating more and more quality-of-life enhancements in their areas despite facing huge constraints on...
The giants of fintech: How Mastercard and PayPal stay afloat during financial technology boom
The world of digital finances has come a long way since first wireless transfers changed the way people do business....
The impact of alternative financing on entrepreneurship
One of the biggest obstacles for entrepreneurs is raising their much-needed capital to launch their business. Case in point: 29...
- Sponsored4 days ago
CEO Spotlight: John Fielding, Toronto entrepreneur, founder of Array Marketing
- Crypto5 days ago
Why a cryptocurrency payment system makes companies competitive
- Business5 days ago
5 tips on selling on social media without driving people away
- Featured4 days ago
Neo banking disrupts fintech